LSLucas Santos

Lucas Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucas Santos has a total of 328 co-authors. Here are the top co-authors by number of shared publications:

  • Carolina Saibro Girardi

    Universidade Federal do Rio Grande do Sul, Brazil

    7 shared publications
  • Daniel Pens Gelain

    Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    7 shared publications
  • José Cláudio Fonseca Moreira

    Department of Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

    6 shared publications
  • Daniel Pens Gelain

    Centro de Estudos em Estresse Oxidativo, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    5 shared publications
  • José Cláudio Fonseca Moreira

    Centro de Estudos em Estresse Oxidativo, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    5 shared publications
  • Felipe Dal-Pizzol

    Laboratory of Experimental Pathophysiology, Graduate Program in Health Sciences, University of Southern Santa Catarina, Criciúma, SC, Brazil

    3 shared publications

Latest Publications

  • Open Access

    Towards Mechanism‐Informed Treatments for Mental Health

    by Iker Bengoetxea de Tena, Farhanah Nabilah Sallie, Arvie Rodriguez Abiero, Beatrice Rizzi, Leandro Gabriel Champarini, Elisa Corti, Gianluca Masella, Ariel L. Dunn, Luisa Bandeira Binder, Tyler J. Wenzel, et al.

    Neuropsychiatric disorders represent a significant global health burden. Despite decades of research, current treatments typically provide only symptomatic relief, rather than addressing the underlying mechanisms of these conditions. Historically, research focused on the dopaminergic and serotonergic systems, which are deeply involved in the pathophysiology of many mental health disorders, including depression, schizophrenia, anxiety, autism spectrum disorder (ASD), and different substance use disorders, including alcohol use disorder (AUD). However, therapies targeting these systems have limitations, often only producing partial symptom relief plus compliance‐limiting side effects. This highlights the need for improved treatments that may emerge from a broader understanding of the neurobiological bases of these conditions, especially neurochemical systems beyond dopamine and serotonin. Additional monoamines (e.g., histamine, acetylcholine, norepinephrine), neurolipid systems (e.g., endocannabinoids), and diverse signaling molecules such as neuropeptides, trace amines, and cytokines are increasingly recognized as key players in the dysfunction of neural circuits. In this review, which originated from the International Society for Neurochemistry (ISN)/Journal of Neurochemistry 5th Flagship School in October 2024 held in Naxos, Greece, we describe the importance of these neuromodulatory systems in the pathophysiology of select neuropsychiatric disorders, discuss their potential as targets for therapeutic intervention, exploring how they may offer more effective, mechanism‐based treatments. We also highlight recent clinical trials, underscoring the progress in advancing towards clinical application, as well as sex‐specific neurobiological differences, a historically overlooked, yet fundamental determinant of the pathophysiology of neuropsychiatric disorders. We propose that expanding our focus beyond traditional monoamines offers a promising avenue for the development of new, disease‐modifying treatments that can more effectively address the underlying causes of neuropsychiatric disorders. By targeting these pathways, we believe it may be possible to develop therapies that restore balance to dysregulated brain circuits and improve long‐term outcomes for patients. image

  • Open Access

    Metformin Ameliorates Cognitive Deficits and Neuroinflammation in a Mouse Model of Familial Hypercholesterolemia

    by Natália Baltazar Do Nascimento, Hémelin Resende Farias, Tainá Schons, Alex Paulo Zeferino Padilha, Mariana Viana Costa, Ariadni Mesquita Peres, Lucas Dos Santos da Silva, Ricardo Maia Dantas, Jessica Marques Obelar Ramos, Matheus Scarpatto Rodrigues, et al.

    Familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein receptor (LDLr) gene, has been increasingly associated with neurodegenerative and mood disorders. Studies with LDLR knockout mice (LDLr −/− ) showed that neuroinflammation is a key event in FH-related brain dysfunction. Because mTOR inhibition has been shown to mitigate brain alterations in this model, we hypothesized that metformin, a drug reported to influence cellular energy metabolism, could attenuate FH-associated brain changes. To test this, adult LDLr −/− mice received daily oral doses of metformin (200 mg/Kg) or vehicle for 30 days. During the final week, behavioral assessments were conducted, including the open-field test, novel object recognition and object reallocation tasks, and the tail suspension test (depressive-like behavior). Body weight, total cholesterol and glucose plasma levels were analyzed. Hippocampal astrocyte and microglial density, as well as the expression of genes related to neuroinflammation and synaptic plasticity, were evaluated. Metformin did not alter total cholesterol levels but significantly improved cognitive performance and reduced depressive-like behavior. The treatment also attenuated hippocampal astrogliosis without affecting microglial reactivity. Molecular analysis revealed reduced hippocampal TGF-β gene expression and increased PSD-95 gene expression and protein content in metformin-treated LDLr −/− mice. Although a slight, non-significant reduction in the phosphorylated-to-total mTOR ratio was detected, no clear evidence of AMPK/mTOR pathway modulation was observed. Overall, metformin improved memory function and astrocyte reactivity in LDLr −/− mice independently of cholesterol reduction and without demonstrable involvement of the AMPK/mTOR pathway, suggesting its potential as a therapeutic strategy for FH-associated brain dysfunction.


  • Histone Acetylation Modifications and HDACs are Associated with Resilience or Susceptibility to Stress in a Rat Model of Major Depressive Disorder

    by Lucas Santos, Luana Possa, Nicole Fröhlich, Luiza Behrens, Camila Barbosa, Camila Tiefensee-Ribeiro, Daniel Pens Gelain, Roberto F. Almeida, José Cláudio Fonseca Moreira

    Major Depressive Disorder (MDD) is a multifactorial psychiatric condition. Evidence shows that stress plays a fundamental role in the pathophysiology of MDD. Studies have hypothesized that some changes in histone acetylation patterns and histone deacetylase (HDACs) are closely associated with the development of MDD. Histone acetylation and deacetylation are covalent modifications that influence chromatin structure, serving as key mechanisms for controlling gene expression. The aim of this study was to investigate the involvement of H2AK5ac, H2BK5ac, H3K9ac, and H4K8ac, as well as HDACs, HDAC1-7 in rats subjected to the chronic unpredictable moderate stress (CUMS) model. For this, 29 male Wistar rats were exposed to the CUMS protocol or designated as a control group. After behavioral tests the animals were classified as resilient or susceptible to the depressive-like phenotype. Subsequently, the acetylation patterns of histones and HDACs were evaluated in the hypothalamus, hippocampus, and parietal cortex. Observing sucrose consumption, open field behavior, and object recognition, it is possible to identify characteristic phenotypes of animals that are either susceptible to the depressive-like phenotype or resilient to the CUMS protocol. For the first time, it was demonstrated that the H3K9ac, H4K8ac, HDAC2, HDAC3, HDAC4, and HDAC5 patterns are associated with resilience or susceptibility to the depressive-like phenotype in a brain region-specific manner. Results from this study provide evidence that H3 and H4 acetylation’s and HDACs are connected with the development of the resilient or susceptible depressive-like phenotype, hence contributing to new advances in understanding the pathophysiology of MDD and discovering mechanisms behind resilience.


  • Neuroprotective Role of Ketamine in Reducing Neuroinflammation and Enhancing Neuroplasticity Against a Cortisol-Induced In Vitro Stress Model

    by Lucas Santos, Fernanda dos Santos Petry, Carolina Saibro-Girardi, Júlia Hansen, Danielle Martins, Nicole Fröhlich, Luana Possa, Luiz Filipe Bastos Mendes, Hémelin Resende Farias, Alberto Martins Silva, et al.

    Stress is widely recognized as a major environmental factor contributing to the development of mood disorders. In patients with Major Depressive Disorder (MDD) and suicidal behavior, significant hyperactivation of the hypothalamic–pituitary–adrenal (HPA) axis is observed, characterized by excessive cortisol release, which in turn stimulates the production of pro-inflammatory mediators. Inflammation affects approximately one in four patients with MDD and is associated with treatment resistance. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist used in patients with severe and treatment-resistant MDD, has emerged as a relevant target for investigation. However, the precise mechanism of action of this drug remains unclear. In this study, we investigated the neuroprotective effects of ketamine in response to cortisol using in vitro stress models with neural-like cells. We observed that cortisol reduced cell viability, increased the expression of inflammatory genes such as NF-κB and NLRP3, and enhanced the production of reactive oxygen species. Additionally, cortisol impaired neuroplasticity by reducing BDNF expression and diminishing the number and length of primary and secondary neurites, as well as overall neural connectivity. Ketamine was found to prevent, attenuate, and even reverse cortisol-induced expression of inflammatory genes and reactive species production. Moreover, ketamine significantly increased BDNF expression and promoted the growth and elongation of primary neurites and neural connections. For the first time, using an in vitro model of cortisol-induced stress in neural-like cells, we demonstrated that ketamine’s mechanism of action extends beyond NMDA receptor antagonism to include the reduction of neuroinflammation and the enhancement of neuroplasticity.


  • Open Access

    Estimating the replicability of Brazilian biomedical science

    by The Brazilian Reproducibility Initiative, Olavo Bohrer Amaral, Clarissa França Dias Carneiro, Kleber Neves, Ana Paula Wasilewska Sampaio, Bruna Valério Gomes, Mariana Boechat de Abreu, Pedro Batista Tan, Gabriel Paz Souza Mota, Ricardo Netto Goulart, et al.

    Concerns over the replicability and reproducibility of published research have grown in many research fields, but empirical data to inform policies are still scarce. Biomedical research in Brazil expanded rapidly over the last three decades, with no systematic assessment of the replicability of its findings. With this in mind, we set up the Brazilian Reproducibility Initiative, a multicenter replication of published experiments from Brazilian science using three common experimental methods: the MTT assay, the reverse transcription polymerase chain reaction (RT-PCR) and the elevated plus maze (EPM). A total of 56 laboratories performed 143 replications of 56 experiments; of these, 90 replications of 45 experiments were considered valid by an independent committee. Replication rates for these experiments varied between 20 and 44% according to five predefined criteria. In median terms, ratios between group means were 58% lower in replications than in original experiments, while coefficients of variation were 82% higher. Effect size decrease was smaller for MTT experiments, original results with less variability and those considered more challenging to replicate, while t values for replications were positively correlated with researcher predictions about replicability, and negatively correlated with the rate of publications by the original article’s last author. Deviations from preregistered protocols were very common in replications, most frequently due to reasons inherent to the experimental model or related to infrastructure and logistics. Our results highlight factors that limit the replicability of results published by researchers in Brazil and suggest ways by which this scenario can be improved.


  • Association of systemic inflammation and long-term dysfunction in COVID-19 patients: A prospective cohort

    by Felipe Dal-Pizzol, Bruno Kluwe-Schiavon, Henrique Ritter Dal-Pizzol, Gabriele da Silveira Prestes, Diogo Dominguini, Carolina Saibro Girardi, Lucas Santos, José Cláudio Fonseca Moreira, Daniel Pens Gelain, Roger Walz, et al.


  • Transgenerational inheritance of methylmercury and vitamin A-induced toxicological effects in a Wistar rats environmental-based model

    by Flávio Gabriel Carazza-Kessler, Marlene Soares Campos, Reykla Ramon Bittencourt, Helen Taís da Rosa-Silva, Pedro Ozorio Brum, Alexandre Kléber Silveira, Alexsander Alves Teixeira, Camila Tiefensee Ribeiro, Daniel Oppermann Peixoto, Lucas Santos, et al.


  • Histone 3 Trimethylation Patterns are Associated with Resilience or Stress Susceptibility in a Rat Model of Major Depression Disorder

    by Lucas Santos, Luiza Behrens, Camila Barbosa, Camila Tiefensee-Ribeiro, Helen Rosa-Silva, Nauana Somensi, Pedro Ozorio Brum, Alexandre Kleber Silveira, Matheus Scarpatto Rodrigues, Jade de Oliveira, et al.

    Major Depressive Disorder (MDD) is a severe and multifactorial psychiatric condition. Evidence has shown that environmental factors, such as stress, significantly explain MDD pathophysiology. Studies have hypothesized that changes in histone methylation patterns are involved in impaired glutamatergic signaling. Based on this scenario, this study aims to investigate histone 3 involvement in depression susceptibility or resilience in MDD pathophysiology by investigating cellular and molecular parameters related to i) glutamatergic neurotransmission, ii) astrocytic functioning, and iii) neurogenesis. For this, we subjected male Wistar rats to the Chronic Unpredictable Mild Stress (CUMS) model of depression. We propose that by evaluating the sucrose consumption, open field, and object recognition test performance from animals submitted to CUMS, it is possible to predict with high specificity rats with susceptibility to depressive-like phenotype and resilient to the depressive-like phenotype. We also demonstrated, for the first time, that patterns of H3K4me3, H3K9me3, H3K27me3, and H3K36me3 trimethylation are strictly associated with the resilient or susceptible to depressive-like phenotype in a brain-region-specific manner. Additionally, susceptible animals have reduced DCx and GFAP and resilient animals present increase of AQP-4 immunoreactivity. Together, these results provide evidence that H3 trimethylations are related to the development of the resilient or susceptible to depressive-like phenotype, contributing to further advances in the pathophysiology of MDD and the discovery of mechanisms behind resilience.


  • Open Access

    Identification of distinct phenotypes and improving prognosis using metabolic biomarkers in COVID-19 patients

    by Andressa Santana, Gabriele da Silveira Prestes, Marinara Dagostin da Silva, Carolina Saibro Girardi, Lucas dos Santos Silva, José Cláudio Fonseca Moreira, Daniel Pens Gelain, Glauco Adrieno Westphal, Emil Kupek, Roger Walz, et al.

    Objective To investigate the relationship between the levels of adipokines and other endocrine biomarkers and patient outcomes in hospitalized patients with COVID-19. Methods In a prospective study that included 213 subjects with COVID-19 admitted to the intensive care unit, we measured the levels of cortisol, C-peptide, glucagon-like peptide-1, insulin, peptide YY, ghrelin, leptin, and resistin.; their contributions to patient clustering, disease severity, and predicting in-hospital mortality were analyzed. Results Cortisol, resistin, leptin, insulin, and ghrelin levels significantly differed between severity groups, as defined by the World Health Organization severity scale. Additionally, lower ghrelin and higher cortisol levels were associated with mortality. Adding biomarkers to the clinical predictors of mortality significantly improved accuracy in determining prognosis. Phenotyping of subjects based on plasma biomarker levels yielded two different phenotypes that were associated with disease severity, but not mortality. Conclusion As a single biomarker, only cortisol was independently associated with mortality; however, metabolic biomarkers could improve mortality prediction when added to clinical parameters. Metabolic biomarker phenotypes were differentially distributed according to COVID-19 severity but were not associated with mortality.


  • Open Access

    Identificação de fenótipos distintos e melhoria do prognóstico usando biomarcadores metabólicos em pacientes com COVID-19

    by Andressa Santana, Gabriele da Silveira Prestes, Marinara Dagostin da Silva, Carolina Saibro Girardi, Lucas dos Santos Silva, José Cláudio Fonseca Moreira, Daniel Pens Gelain, Glauco Adrieno Westphal, Emil Kupek, Roger Walz, et al.

    RESUMO Objetivo Investigar a relação entre os níveis de adipocinas e outros biomarcadores endócrinos e os desfechos em pacientes hospitalizados com COVID-19. Métodos Estudo prospectivo que incluiu 213 indivíduos com COVID-19 internados na unidade de terapia intensiva, em que foram medidos os níveis de cortisol, peptídeo-C, peptídeo-1 semelhante ao glucagon, insulina, peptídeo YY, grelina, leptina e resistina; analisamos suas contribuições para o agrupamento de pacientes, gravidade da doença e previsão de mortalidade hospitalar. Resultados Os níveis de cortisol, resistina, leptina, insulina e grelina diferiram significativamente entre os grupos por gravidade, conforme definido pela escala de gravidade da Organização Mundial da Saúde. Além disso, níveis mais baixos de grelina e mais altos de cortisol foram associados à mortalidade. A adição de biomarcadores aos preditores clínicos de mortalidade melhorou significativamente a precisão na determinação do prognóstico. A fenotipagem de indivíduos com base nos níveis de biomarcadores plasmáticos produziu dois fenótipos diferentes, que foram associados à gravidade da doença, mas não à mortalidade. Conclusão Como único biomarcador, apenas o cortisol foi independentemente associado à mortalidade; no entanto, os biomarcadores metabólicos podem melhorar a previsão de mortalidade quando associados a parâmetros clínicos. Os fenótipos dos biomarcadores metabólicos foram distribuídos diferencialmente, conforme a gravidade da COVID-19, mas não foram associados à mortalidade.